Case study

16 Dec 2020

Phase I Trial Maximum Dose Tolerance / Advanced Cancer Patients


Successful Oncology Phase 1 studies require enrolling subjects quickly, monitoring the trial closely for safety and adhering to the precise timing requirements for cohorts’ “starts” and “stops”. TFS was responsible for this first-in-man dose escalation study designed to determine the maximum tolerated dose (MTD).

The clinical trial was conducted in patients with unresectable, relapsed or refractory advanced solid tumors with no curative therapy options. The population was enrolled under one Principal Investigator at one central site and four satellite offices.


    • Subjects presented with the following cancers — colorectal, NSCLC, ovarian, pancreatic, gastric and breast tumors
    • Protocol design required precise timing of the ‘starts’ and ‘stops’
    • Safety data review and assessment required rapid data turnaround for each cohort

    See Other Case Studies

    TFS involved in European global customer’s pre-lau...

    TFS was requested to prepare and conduct a Late Phase global proposal to support the pre-launch activities of two pro...

    Read more

    How TFS Strategic Resourcing Solutions deployed a ...

    Given the catastrophic spread of COVID-19, the search for safe and effective therapies has taken on an unpreced...

    Read more

    TFS & a Global Biotech Company

    As clinical trials grow increasingly complex, timelines shorten, and R&D costs soar. Today’s biopharmaceuti...

    Read more